The failure rate of its ASR XL hip device may be four times as much as originally claimed by Depuy.
New projected failure rates for Depuy’s ASR XL metal on metal hip implant were announced at the British Hip Society’s annual meeting earlier this month. In a joint statement, the British Hip Society and the British Orthopaedic Association claimed that the revision rate ranged from 21% within four years (although that number could rise to 35% if all currently known painful implants progress to revision) to 49% in six years.
Dr. John Skinner, an orthopedic surgeon and chairman of the British Hip Society’s expert advisory group on metal bearing hips, said of the study, “It’s probably the best indicator so far of what the failure rate is likely to be.”
This study is in stark contrast to an earlier study relied upon by DePuy. In September of 2010, DePuy Orthopaedics, a division of Johnson and Johnson, issued a recall of its ASR XL Acetabular System and ASR Hip Resurfacing Platforms. According to DePuy, the recall was spurred by data that showed a revision surgery rate of about 13 percent for those with the ASR XL system and of about 12 percent for those with the ASR resurfacing system.
If you are experiencing pain or have required surgery after a DePuy Hip Replacement, you need to be evaluated by your surgeon and you need to discuss your legal options.
At Pope McGlamry, our product liability attorneys are presently investigating DePuy Hip Replacement claims. If you suffer chronic pain, limited mobility, or difficulty walking due to a hip replacement, you may be entitled to compensation for your suffering.
Contact our Georgia DePuy Hip Replacement lawyers to discuss your potential lawsuit. We will evaluate your claim and explain your legal options.
Disclaimer: All use of the ASR mark is for informational and product identification purposes only. This post should not be taken as either medical or legal advice, but instead should act as a resource in providing general information that may be useful to the general public. Pope McGlamry is not affiliated with DePuy Orthopaedics, Johnson & Johnson, or their distributors.